Cascade Bancorp's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Cascade Bancorp (CACB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Cascade Bancorp vs Its Competitors
- TTM: Trailing 12-month revenue of 127M vs 5,796M combined for tracked competitors (2.1% combined share).
- Trending: Latest-quarter revenue run-rate is holding steady (+1.6% annualized vs trailing 12 months), vs decelerating (-56.3%) for its tracked peer group.
- Growth: Cascade Bancorp generated 17.1% revenue growth year over year in Q1 2017, vs -14.5% for its tracked competitors combined.
- Profitability: Its 20.9% net margin compares with 3.0% for the peer group.
- Peer revenue share: Cascade Bancorp accounted for 4.9% of combined revenue among its tracked peer group, up from 3.6% a year earlier.
- Peer differentiation: Revenue per employee of $0.25M compares with $0.60M for the peer group (0.4x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
CACB Sales vs. its Competitors, Q1 2017
Cascade Bancorp reported revenue growth of 17.12 % year on year in Q1 2017, above its competitors' combined revenue change of -14.54 %.
With a net margin of 20.91 %, Cascade Bancorp achieved higher profitability than its competitors (3.01 %).
Cascade Bancorp generated 4.86 % of the combined sales of its peer group, up from 3.59 % a year earlier.
Cascade Bancorp vs. its Competitors, Q1 2017
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Cascade Bancorp and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Cascade Bancorp | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (6) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Cascade Bancorp's competitor groups requires a Commercial License.
For context: the Regional Banks industry grew revenue -15.0% year over year, combined, vs 17.1% for Cascade Bancorp. Cascade Bancorp's share of combined industry revenue moved from 0.02% to 0.02%, a gain of 0.01 percentage points.
Cascade Bancorp's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Cascade Bancorp | Yes | Yes | Yes | No |
| Competitors combined (4) | ||||
| Similar Growth & Profitability (8) | 100.00 % (8 of 8) | 100.00 % (8 of 8) | 75.00 % (6 of 8) | 14.30 % (1 of 7) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
CACB Stock Performance relative to its Competitors
CACB Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Bluelinx Holdings Inc | 282.9% | Outperformed |
| 2 | Cavco Industries Inc | 282.9% | Outperformed |
| 3 | Centrus Energy Corp | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Cascade Bancorp's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Publicly Traded Peers of Cascade Bancorp
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Cascade Bancorp | - | 127.30 |
| Cavco Industries Inc | 4,362.31 | 2,312.25 |
| Centrus Energy Corp | 3,072.84 | 473.90 |
| Bluelinx Holdings Inc | 588.66 | 3,009.90 |
| Ngm Biopharmaceuticals Inc | 127.04 | 4.42 |
| SUBTOTAL | 8,150.85 | 5,927.77 |
Sources: Cascade Bancorp's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Cascade Bancorp versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Cascade Bancorp's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Cavco Industries Inc | Named by the company | 85% |
| Centrus Energy Corp | Named by the company | 85% |
| Bluelinx Holdings Inc | Named by the company | 85% |
| Ngm Biopharmaceuticals Inc | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Cascade Bancorp's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Cascade Bancorp's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Cavco Industries Inc | Factory Built Housing 93.77 % |
| Bluelinx Holdings Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Cascade Bancorp's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Cascade Bancorp | - | 248,140 | 42,092 |
| Cavco Industries Inc | 4,362 | 330,322 | 25,883 |
| Centrus Energy Corp | 3,073 | 1,014,775 | 103,854 |
| Bluelinx Holdings Inc | 589 | 1,393,472 | -902 |
| Ngm Biopharmaceuticals Inc | 127 | 44,170 | -1,423,750 |
| PEERS TOTAL | 8,151 | 596,327 | 8,775 |
Cascade Bancorp's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Regional Banks industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (130 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 69.94 % | 64.14 % (avg) | +5.8 pp |
| Operating Margin | 30.12 % | industry median | -7.8 pp |
| EBITDA Margin | 32.26 % | 49.90 % (avg) | -17.6 pp |
| Capital Intensity (Capex / Revenue) | - | 3.18 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Cascade Bancorp's Valuation vs Competitive Position
Valuation multiples vs the Regional Banks industry average (130 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | 26.2x | 15.6x | +10.6x |
| EV / EBITDA | -0.8x | 6.2x | -7.0x |
| P/B | 1.6x | 1.3x | +0.3x |
| Return on Equity | 5.91 % | industry aggregate | -2.71 % |
| Return on Invested Capital | 4.89 % | 3.20 % (avg) | 1.69 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Cascade Bancorp's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2013 | 2014 | 2015 | 2016 |
|---|---|---|---|---|
| Revenue Growth | -0.33 % | 38.25 % | 26.08 % | 14.03 % |
| Operating Margin | - | - | 30.79 % | - |
| Return on Invested Capital | - | - | 4.68 % | - |
| P/E | - | - | 19.7x | 31.4x |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Cascade Bancorp's Strategic Group Map
Every company in Cascade Bancorp's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Cascade Bancorp is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Cascade Bancorp's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Cascade Bancorp falls in the High attractiveness / Medium strength cell: Invest / Grow.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Cascade Bancorp's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Operating margin 7.8 points below the industry median.
Opportunities
- Industry revenue growing at a healthy 12.3% median pace.
- A meaningful share of tracked competitors (50.00 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-56.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Cascade Bancorp's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Cascade Bancorp | 0.05 | 0.99 | - |
| Cavco Industries Inc | 0.97 | 2.63 | - |
| Centrus Energy Corp | 3.90 | 4.86 | 1.71 |
| Bluelinx Holdings Inc | 1.48 | 4.26 | 0.72 |
| Ngm Biopharmaceuticals Inc | 2.10 | 7.18 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Cascade Bancorp's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Cascade Bancorp | Q1 2017 | +17.1 % | +248.6 % |
| Cavco Industries Inc | Q2 2026 | +12.3 % | -18.1 % |
| Centrus Energy Corp | Q2 2026 | +14.0 % | -41.9 % |
| Bluelinx Holdings Inc | Q2 2026 | +4.4 % | +48.6 % |
| Ngm Biopharmaceuticals Inc | Q4 2023 | -99.1 % | - |
| PEERS TOTAL | +7.2 % | -11.5 % |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Cascade Bancorp's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Cascade Bancorp | Q1 2017 | - | - |
| Cavco Industries Inc | Q2 2026 | +11.4 % | +179.0 % |
| Centrus Energy Corp | Q2 2026 | +25.4 % | +1,888.9 % |
| Bluelinx Holdings Inc | Q2 2026 | +2.1 % | -75.2 % |
| Ngm Biopharmaceuticals Inc | Q4 2023 | - | -57.4 % |
Cascade Bancorp's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Cascade Bancorp | 0.70% | 5.16% | 5.91% |
| Cavco Industries Inc | 12.31% | 15.91% | 16.61% |
| Centrus Energy Corp | 2.01% | 2.50% | 7.06% |
| Bluelinx Holdings Inc | - | - | - |
| Ngm Biopharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Cascade Bancorp's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Cascade Bancorp | - | - |
| Cavco Industries Inc | 24.47 | 1.89 |
| Centrus Energy Corp | 61.03 | 6.48 |
| Bluelinx Holdings Inc | - | 0.20 |
| Ngm Biopharmaceuticals Inc | - | 28.76 |
| PEERS AVERAGE | 76.21 | 1.38 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.